VEGFR-2-receptor - target for anticancer therapy
Journal Title: Współczesna Onkologia - Year 2006, Vol 10, Issue 10
Abstract
Vascular endothelial growth factor (VEGF) is a potent mitogen that plays a key role in the growth and maintenance of vascular endothelial cells as well as in the development of new physiological and tumour blood vessels. Among cell surface receptors responsible for internalizing this growth factor is VEGFR-2, a member of the receptor type tyrosine kinase superfamily. Following VEGF-mediated activation of this receptor in tumour endothelial cells, a series of biochemical events is initiated, leading to division of these cells and, subsequently, to the formation of new tumour blood vessels. This review presents molecular strategies of targeting the VEGFR-2 receptor for therapeutic purposes. Some of these strategies have been attaining preclinical or clinical stage of development, e.g. anti-VEGFR-2 antibodies, cyclic peptides, two-domain peptides, low-molecular-weight tyrosine kinase inhibitors or antisense oligonucleotides blocking VEGFR-2 expression. Attempts have also been made to take advantage of the immune response directed against blood vessels exhibiting this receptor.
Authors and Affiliations
Joanna Hucz, Stanisław Szala
Keywords
Related Articles
- EP ID EP82476
- DOI -
- Views 73
- Downloads 0
c-myc oncogene aberration in breast cancer patients assessed by direct double differential PCR
Breast cancer is the most frequent tumour diagnosed in women, especially in well-developed countries. One of the genes of the highest interest in its diagnosis and prognosis is protooncogene c-myc, which plays a role as...
Utylizacja radu 226 z ośrodka onkologicznego – ocena narażenia personelu
226Ra znalazł zastosowanie w terapii onkologicznej ze względu na długi okres połowiczego rozpadu i rodzaj emitowanego promieniowania. Po wielu latach stosowania zastąpiono go izotopami krótkożyciowymi, charakteryzujący...
Adjuvant endocrine therapy in breast cancer
Endocrine therapy is the most important component of adjuvant therapy for patients with hormone receptor-positive breast cancer, regardless of age and menopausal status. Tamoxifen improves survival in premenopausal and...
Cancer procoagulant (CP) in surgical oncology diagnostics
A considerable advancement of the neoplastic process at the start of the treatment is one of the major reasons of high mortality caused by malignant neoplasms. Numerous studies have been devoted to the diagnosis of cance...
Chemioterapia zaawansowanego raka jelita grubego z zastosowaniem irinotekanu
Irinotekan (CPT-11) jest półsyntetyczną pochodną kamptotecyny, poddaną badaniom szczególnie intensywnym w przypadku raka jelita grubego, gdzie znalazł szerokie zastosowanie. Wyniki badań fazy I i II były bardzo zachęcają...